1
|
Newman C, Kinsella S, Rooney P, Bromley J, Connor R, Gajewska K, Hannan S, Holt RIG, Hubbard J, Kavangh C, Moffett J, Morris A, Nathan H, Oliver N, Petrie JR, Skarlatos M, Treanor D, Williams P, Dunne FP. The top 10 priorities in adults living with type 1 diabetes in Ireland and the United Kingdom - A James Lind Alliance priority setting partnership. Diabet Med 2024; 41:e15429. [PMID: 39160771 DOI: 10.1111/dme.15429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2024] [Accepted: 08/08/2024] [Indexed: 08/21/2024]
Abstract
AIMS To undertake a Priority Setting Partnership (PSP), identifying the most important unanswered questions in type 1 diabetes in Ireland and the United Kingdom and to compare these to priorities identified in a 2011 PSP. METHODS A steering committee (including eight individuals with lived experience/charity representatives and six clinicians) designed a survey which asked stakeholders to list three questions about type 1 diabetes. This was disseminated through social media, direct email contact, and printed posters. Following analysis, a second survey asked participants to rank these priorities in order of importance. The top questions were then carried forward to an online, 2 days final workshop where the final top 10 were ranked. RESULTS There were 1050 responses (64% female, 78% adults living with type 1 diabetes, 9% healthcare professionals, 9% family members) to the first survey and 2937 individual questions were submitted. Sixty-five summary questions were submitted into a second survey, completed by 497 individuals (76% adults living with type 1 diabetes, 9% healthcare professionals, and 11% family members). Nineteen questions from the interim survey progressed to a final workshop, which identified the top 10 priorities through group discussion. As in 2011, there was emphasis on psychological health, diabetes-related complications, and hypoglycaemia. New themes prioritised included artificial intelligence and women's health. CONCLUSIONS The research priorities, which have been identified using a robust and proven methodology, highlight the key concerns of those living with type 1 diabetes, their families and representatives, as well as clinicians in Ireland and the UK.
Collapse
Affiliation(s)
- Christine Newman
- Institute for Clinical Trials, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland
- Irish Collaborative Clinical Trial Network in Diabetes, University of Galway, Galway, Ireland
- Galway University Hospital, Galway, Ireland
| | - Suzannah Kinsella
- James Lind Alliance, National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre, University of Southampton, Southampton, UK
| | - Peter Rooney
- Institute for Clinical Trials, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland
| | - Jake Bromley
- Diabetes Collaborative Clinical Trials Network Public and Patient Involvement Department, University of Galway, Galway, Ireland
| | - Rachel Connor
- Breakthrough T1D (Formerly Juvenile Diabetes Research Foundation), London, UK
| | - Kate Gajewska
- Diabetes Ireland, Northwood Business Campus, Dublin, Ireland
| | - Sinead Hannan
- Southern Trust, Health and Social Care, Craigavon, UK
| | - Richard I G Holt
- Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK
| | - Julia Hubbard
- Breakthrough T1D (Formerly Juvenile Diabetes Research Foundation), London, UK
| | - Columb Kavangh
- Diabetes Collaborative Clinical Trials Network Public and Patient Involvement Department, University of Galway, Galway, Ireland
| | - Jinty Moffett
- Diabetes Collaborative Clinical Trials Network Public and Patient Involvement Department, University of Galway, Galway, Ireland
| | | | - Hilary Nathan
- Breakthrough T1D (Formerly Juvenile Diabetes Research Foundation), London, UK
| | | | - John R Petrie
- School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | | | - David Treanor
- Diabetes Collaborative Clinical Trials Network Public and Patient Involvement Department, University of Galway, Galway, Ireland
| | - Pauline Williams
- Diabetes Collaborative Clinical Trials Network Public and Patient Involvement Department, University of Galway, Galway, Ireland
| | - Fidelma P Dunne
- Institute for Clinical Trials, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland
- Irish Collaborative Clinical Trial Network in Diabetes, University of Galway, Galway, Ireland
- Galway University Hospital, Galway, Ireland
| |
Collapse
|
2
|
Riddell MC, Shakeri D, Scott SN. A Brief Review on the Evolution of Technology in Exercise and Sport in Type 1 Diabetes: Past, Present, and Future. Diabetes Technol Ther 2022; 24:289-298. [PMID: 34809493 DOI: 10.1089/dia.2021.0427] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
One hundred years ago, insulin was first used to successfully lower blood glucose levels in young people living with what was then called juvenile diabetes. While insulin was not a cure for diabetes, it allowed individuals to resume a near normal life and have some freedom to eat more liberally and gain the strength they needed to live a more active lifestyle. Since then, a number of therapeutic and technical advances have arisen to further improve the health and wellbeing of individuals living with type 1 diabetes, allowing many to participate in sport at the local, regional, national or international level of competition. This review and commentary highlights some of the key advances in diabetes management in sport over the last 100 years since the discovery of insulin.
Collapse
Affiliation(s)
- Michael C Riddell
- School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Canada
| | - Dorsa Shakeri
- School of Kinesiology and Health Science, Muscle Health Research Centre, York University, Toronto, Canada
| | - Sam N Scott
- Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Bern University Hospital, University of Bern, Bern, Switzerland
- Team Novo Nordisk Professional Cycling Team, Atlanta, Georgia, USA
| |
Collapse
|
4
|
Brener A, Mazor-Aronovitch K, Rachmiel M, Levek N, Barash G, Pinhas-Hamiel O, Lebenthal Y, Landau Z. Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown. Acta Diabetol 2020; 57:1511-1517. [PMID: 33026497 PMCID: PMC7538839 DOI: 10.1007/s00592-020-01596-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Accepted: 08/12/2020] [Indexed: 02/05/2023]
Abstract
AIMS Billions of people have been under lockdown in an attempt to prevent COVID-19 spread. Lifestyle changes during lockdown could lead to deterioration of glycemic control in type 1 diabetes (T1D). We aimed to assess the impact of COVID-19 lockdown on the glycemic control of pediatric patients with T1D. METHODS This observational real-life study from the AWeSoMe Group assessed continuous glucose monitoring (CGM) metrics of 102 T1D patients (52.9% males, mean age 11.2 ± 3.8 years, mean diabetes duration 4.2 ± 3.8 years) who used Dexcom G5. The data were accessed without any interface between patients, caregivers, and the diabetes team. Study variables from CGM metrics were: mean glucose level, time-in-range (TIR, 70-180 mg/dL; 3.9-10 mmol/L), hypoglycemia (< 54 mg/dL; < 3 mmol/L), hyperglycemia (> 250 mg/dL; > 13.3 mmol/L), coefficient of variation (CV), and time CGM active before and during lockdown. Delta-variable = lockdown variable minus before-lockdown variable. RESULTS The mean TIR was 60.9 ± 14.3% before lockdown, with no significant change during lockdown (delta-TIR was 0.9 ± 7.9%). TIR during lockdown was significantly correlated with TIR before lockdown (r = 0.855, P < 0.001). Patients with improved TIR (delta-TIR > 3%) were significantly older than patients with stable or worse TIR (P = 0.028). Children aged < 10 years had a significantly higher CV before lockdown and during lockdown than children aged ≥ 10 years (P = 0.02 and P = 0.005, respectively). Among children aged < 10 years, a multiple linear regression model revealed associations of age and lower socioeconomic cluster with delta-TIR (F = 4.416, P = 0.019) and with delta-mean glucose (F = 4.459, P = 0.018). CONCLUSIONS CGM metrics in pediatric patients with T1D were relatively stable during a nationwide lockdown. Intervention plans should focus on younger patients with lower socioeconomic position.
Collapse
Affiliation(s)
- Avivit Brener
- Pediatric Endocrinology and Diabetes Unit, Dana Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
| | - Kineret Mazor-Aronovitch
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Pediatric Endocrine and Diabetes Unit, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Ramat-Gan, Israel
- National Juvenile Diabetes Center, Maccabi Health Care Services, Ra'anana, Israel
| | - Marianna Rachmiel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Pediatric Endocrinology Unit, Shamir (Assaf Harofeh) Medical Center, Tzrifin, Israel
| | - Noa Levek
- National Juvenile Diabetes Center, Maccabi Health Care Services, Ra'anana, Israel
| | - Galia Barash
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Pediatric Endocrinology Unit, Shamir (Assaf Harofeh) Medical Center, Tzrifin, Israel
| | - Orit Pinhas-Hamiel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Pediatric Endocrine and Diabetes Unit, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Ramat-Gan, Israel
- National Juvenile Diabetes Center, Maccabi Health Care Services, Ra'anana, Israel
| | - Yael Lebenthal
- Pediatric Endocrinology and Diabetes Unit, Dana Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Zohar Landau
- National Juvenile Diabetes Center, Maccabi Health Care Services, Ra'anana, Israel
- Pediatrics Department, Barzilai Medical Center, Ashkelon, Israel
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| |
Collapse
|